Extracorporeal membrane oxygenation improves coagulopathy in an experimental traumatic hemorrhagic model by unknown
1 3
DOI 10.1007/s00068-016-0730-1
Eur J Trauma Emerg Surg
ORIGINAL ARTICLE
Extracorporeal membrane oxygenation improves coagulopathy 
in an experimental traumatic hemorrhagic model
M. Larsson1,2  · P. Forsman2 · P. Hedenqvist6 · A. Östlund4 · J. Hultman2 · 
A. Wikman5 · L. Riddez1,3 · B. Frenckner2 · M. Bottai7 · C.‑M. Wahlgren1,3 
Received: 25 March 2016 / Accepted: 20 July 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
and were hemorrhaged 45% of their estimated blood volume. 
After 90 min of hemorrhagic shock they were resuscitated 
with a standard transfusion protocol together with venoarterial 
ECMO (n = 5) or with a standard transfusion protocol only 
(n = 5) for 60 min. No systemic heparin was administered.
Results ECMO during 60 min of resuscitation significantly 
increased heart rate (p = 0.01), mean arterial pressure 
(p = 0.01), body temperature (p = 0.01) and improved the 
metabolic acidosis, pH (p = 0.01), and lactate (p = 0.01). 
ECMO also improved the coagulation capacity measured 
in vitro by Rotational Thromboelastometry with a signifi-
cant decrease in clot formation time (p < 0.01). This finding 
was confirmed in vivo with a significant reduction in the 
animals’ ear bleeding time (p < 0.01) and cuticle bleeding 
time (p < 0.01); 5/5 animals survived in the ECMO group 
and 3/5 animals survived in the control group.
Conclusions Heparin-free ECMO stabilizes circulation, 
improves coagulation, and may impact short-time survival, 
during the first 60 min, in an experimental traumatic model 
with severe hemorrhagic shock.
Keywords Trauma · Shock · Coagulopathy · Animal 
model · Extracorporeal circulation · ECMO · Hemorrhage · 
Resuscitation
Introduction
Major trauma is the leading cause of death worldwide in the 
young population. Hemorrhage is the most common pre-
ventable cause of death after trauma and accounts for up to 
30–40% of trauma-related deaths [1–4]. Early resuscitation 
emphasizes adequate ventilation, damage control surgery 
(DCS) with rapid control of bleeding, blood transfusion, 
and prevention or early management of coagulopathy [5, 6].
Abstract 
Purpose Hemorrhage is the most common cause of pre-
ventable death after trauma. Coagulopathy plays a central 
role in uncontrolled bleeding and is caused by multiple fac-
tors. Extracorporeal Membrane Oxygenation (ECMO) is an 
established treatment for patients with respiratory failure 
and has in recent years also been used in severely injured 
trauma patients with cardiopulmonary failure and coexist-
ing bleeding shock. The aim of this study was to evaluate 
the effect of ECMO on hypothermia, acidosis, and coagu-
lopathy in a traumatic hemorrhagic rabbit model.
Methods After anesthesia and tracheostomy, ten New Zealand 
White rabbits sustained laparotomy, bilateral femur fractures 
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Acute traumatic coagulopathy (ATC) is multifactorial, 
involves the whole process of hemostasis, and is associ-
ated with severe injury. Six key factors for initiation of 
ATC have been identified. They are tissue trauma, shock, 
hemodilution, hypothermia, acidosis, and inflammation [7]. 
Tissue injury needs to be combined with hypoperfusion 
of organs to induce ATC [8]. Acidosis is mainly the result 
of hypoperfusion and impairs the function of clotting fac-
tors. Hypothermia and metabolic acidosis are late effects of 
bleeding shock and clearly enhance coagulopathy. Acido-
sis and hypothermia do not seem to cause clinical relevant 
effects on protease function until pH is <7.2 and tempera-
tures are under 33 °C. Platelet function and aggregation are 
reduced at temperatures lower than 35 °C [9–12]. Extra-
corporeal Membrane Oxygenation (ECMO) has been an 
established treatment for severe respiratory failure for more 
than 20 years [13, 14]. ECMO treatment in trauma patients 
with severe hypoxia due to pulmonary contusions or acute 
respiratory distress syndrome (ARDS) has previously been 
described [15]. In severe hemorrhage with hemodynamic 
compromise ECMO therapy is less well established even 
though occasional reports on immediate ECMO in multi-
trauma have been published [16–19].
This is a proof-of-concept study and the aim was to inves-
tigate if venoarterial ECMO (VA–ECMO) could reverse aci-
dosis, hypothermia, and coagulopathy in a traumatic hemor-
rhagic rabbit model during the initial 60 min of resuscitation.
Materials and methods
Study animals and control group
15 male New Zealand White rabbits (mean weight 3.85 kg) 
were used in an experimental trauma model with bilateral 
femur fractures, laparotomy, and a class IV bleeding shock 
(>40% hemorrhage of blood volume) (Fig. 1). Five rabbits, 
the control group, were treated with a standard transfusion 
protocol meaning transfusion of citrated whole blood, cal-
cium, and active rewarming. Another five rabbits, the ECMO 
group, received the same treatment as the former group but 
were also on venoarterial ECMO (VA–ECMO) for 60 min 
(Fig. 2). Finally, five rabbits were used as blood donors for 
priming the ECMO-circuits (one rabbit/circuit). All rabbits 
were siblings with blood group B. The ECMO model was 
previously developed and used [20].
Outcomes
The primary outcomes were coagulation status, pH, lactate, 
base excess, and body temperature after 60 min of resusci-
tation. Secondary outcomes were heart rate, mean arterial 
pressure, and short-term survival.
Anesthesia
For premedication medetomidine (0.2 mg/kg) was adminis-
tered subcutaneously. Total intravenous anesthesia (TIVA) 
was performed with sufentanil (6.9 mg/kg per hour and 
midazolam (1.35 mg/kg per hour). Before initiation of the 
femur fractures, the TIVA was changed to ketamine infu-
sion (12.5–25 mg/kg/h) for the remainder of the experi-
ment. No neuromuscular blocking agents were used.
Instrumentation
Percutaneous venous catheters were placed in both ears 
for administration of drugs. An arterial line was placed in 
the right ear artery for blood pressure monitoring before 
the hemorrhage phase in both groups and during the 
Fig. 1  The Rabbit ECMO-Trauma model. The animal sustained 
laparotomy and bilateral femur fractures and were exsanguinated to 
class IV Shock. The venoarterial ECMO circuit: Venous draining can-
nulae in the right atrium (blue), roller pump, heparinized membrane 
oxygenator for saturation and carbondioxide removal, water heat 
exchanger (38.5 °C). Blood is reinfused in the descending aorta (red). 
Bilateral femurfractures are indicated
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resuscitation phase in the ECMO group. 5 Fr introducers 
were placed in the inferior vena cava (IVC) and descending 
aorta (DA). The vessels were cannulated for blood drain-
age and potential connection to an ECMO system. Arterial 
pressure was controlled in the DA during the hemorrhage 
phase in both groups and during the resuscitation phase in 
the control group. If the animal was to be treated with VA-
ECMO, the IVC was cannulated with a 12 Fr Fem-Flex II 
venous cannula (Edwards Lifesciences™) with the tip in 
the right atrium of the heart. The DA was cannulated with 
the tip pointing towards the heart with an 8 Fr Fem-Flex II 
arterial cannula (Edwards Lifesciences™) (Fig. 1).
Ventilation and ECMO
The animals were tracheotomized with a 3.5 mm cuffed 
endotracheal tube and put on pressure controlled mechani-
cal ventilation with 25–30% oxygen, 8–15 breaths/min with 
4 cmH2O post end expiratory pressure (PEEP) and peak 
pressure of 20 cmH2O (Servo 900 C
®, Siemens-Elema). 
Repeated blood gas analyses were performed (ABL 800, 
Radiometer) and ventilation was adjusted accordingly aim-
ing for normoventilation before trauma was induced.
The ECMO circuit was custom-made and consisted of a 
Stöckert® roller pump, a Medos® Hilite LT Infant 800 oxy-
genator and ¼” surface-heparinized standard tubings of 200 
cm length. The blood was warmed 38.5 °C using a water-
filled heat exchanger (HICO-Aquaterm 660, Hirtz). The 
ECMO systems were primed with 120 ml of citrated blood 
from the donor rabbits. Citrate ratio: 1 part sodium citrate 
2.63 g/L (Macopharma®)/12 parts blood). No heparin was 
added and no transfusion reactions were observed. Sweep 
gas flow over the oxygenator was set on O2 1000 ml/min 
and CO2 50 ml/min, to inhibit elimination of CO2 over the 
oxygenator (Fig. 1).
Monitoring
The animals were monitored continuously with electrocar-
diogram (ECG); mean arterial pressure (MAP), esophageal 
temperature, saturation of the tongue and end-tidal CO2.
Traumatic hemorrhage phase
The rabbits initially sustained midline laparotomies and 
bilateral femur fractures. The fractures were located cen-
trally on both femurs using two small pipe wrenches with 
a distance of 2 cm. By fixating both ends of the femurs 
with the pipe wrenches and moving the wrenches shafts 
apart, mid-shaft femur fractures were induced on both sides 
of each study animal. 45% of the rabbits estimated blood 
volume (70 ml/kg) was drawn with syringes from the IVC 
continuously during 30 min. The drained blood was citrated 
(ratio 1/12) and stored in a blood warmer at 38.5 °C. The 
animals were kept in hemorrhagic shock for an additional 
60 min. Ringer’s solution was infused to keep the MAP at 
approximately 20 mmHg, a temperature of less than 32 °C 
and a pH below 7.3. The total hemorrhagic shock time was 
90 min (Fig. 2).
Resuscitation phase
After the traumatic hemorrhage shock phase, the resuscita-
tion phase started. The control group was transfused dur-
ing 30 min with warm citrated blood (38.5 °C), followed 
by rewarming with a heating mattress for another 30 min. 
If calcium levels fell below 1.0 mmol/L, calcium was sub-
stituted (Calcium Sandoz®).The ECMO group received the 
same treatment as the control group and VA-ECMO with a 
flow rate of 100 ml/kg/min for 60 min, in addition (Figs. 1, 
2). At the end of the experiment (150 min) all animals 
were killed in deep anesthesia with Pentobarbitalnatrium® 
120 mg/kg (Fig. 2).
Blood chemistry and coagulation status
Blood-gasses were drawn every 15 min and analyzed 
immediately for pH, pCO2, pO2, Base Excess (BE), Hemo-
globin, Hematocrit, K+, Na+, Ca2+, Cl−, Glucose, and 
Lactate.
At baseline (0 min), after 90 min of hemorrhagic shock 
and after 60 min of resuscitation, or when it was obvious 
that asystole was to occur within minutes, the following 
0 90 150
Trauma/Hemorrhage (45%) Resuscitation+/- ECMO
min-30
Fig. 2  Flowchart illustrating the study’s timeline. Induction of anes-
thesia was at −30 min. All rabbits (n10) sustained laparotomy and 
femurfractures at baseline, 0 min. During 30 min blood was drained 
from the IVC. The animals were kept in bleeding shock for another 
60 min (goals were mean arterial pressure <20 mmHg, tempera-
ture <32 °C, and pH < 7.3). At 90 min resuscitation began with a 
standard protocol (n = 5) or with a standard protocol and venoarte-
rial ECMO in addition (n = 5). Rotational thromboelastometry and 
standard coagulation tests were controlled at 0, 90 and 150 min. The 
animals were killed at 150 min
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coagulation tests were controlled—activated partial throm-
boplastin time (aPTT), D-dimer, fibrinogen concentration, 
fibrin, prothrombincomplex(PT)/international normalized 
ratio (INR), platelet count (PLT), and ROTEM.
Rotem
The ROTEM® analyses were performed on whole blood, 
collected in tubes containing 0.129 mol l−1 sodium cit-
rate and analyzed according to manufacturer’s instruction 
ROTEM® Delta 3000 (TEM innovations, GmbH, München, 
Germany). Analyses were performed within 30 min at 
a temperature adjusted to the actual rabbit’s body tem-
perature. The variables analyzed in ROTEM were extrin-
sic pathway (EXTEM) and intrinsic pathway (INTEM). 
Clotting time (CT) reflected the time until initiation of a 
clot. Clot formation time (CFT) reflected the time until a 
4 mm clot was formed. EXTEM maximum clot firmness 
(MCF) reflected the stability of the clot. Fibrinogen func-
tion (FIBTEM) and heparin effect (HEPTEM) were also 
analyzed.
Bleeding time
In vivo bleeding times were controlled at baseline, at the 
end of resuscitation or prior to asystole. Bleeding time was 
controlled as follows. The animals’ Ear Bleeding Time 
(EBT) was tested with Surgicut ® Jr (SUJ 50i) and blotting 
paper in both ears [21]. The cuticle bleeding time (CBT) 
was also measured with a standardized incision in the sec-
ond digit of the right front foot by cutting the claw with a 
sharp nail clipper, including the apex of the cuticle, thereby 
inducing a combined arterial and venous bleeding [22].
Statistical analyses
The statistical analyses were made by the Biostatistics 
Core Facility, Karolinska Institutet. All the outcome vari-
ables described in the above subsections were considered. 
The outcome variables were analyzed one at a time. Each 
outcome variable was compared between the two treat-
ment arms over the study follow-up period from baseline 
to 150 min. For each outcome variable, the mean value 
was estimated over follow-up time and by treatment arm 
with a linear regression model that included minutes since 
intervention as categorical variable, the binary indicator for 
treatment, and all pair-wise interaction terms. The standard 
errors were obtained with a cluster robust estimator that 
took the within animal dependence into account [23]. The 
animals represented the clusters. The estimated means and 
95% confidence intervals are reported in the figures. The 
differences between means of outcome variable at 90 min 
and at 150 min were obtained from the robust regression 
models. In addition, the distribution of each outcome vari-




After traumatic injury and 90 min of hemorrhagic shock, 
all animals (n = 10) were in a critical state with bradycar-
dia (<100 bpm) and fulfilled the set criteria of hypotension 
(MAP ≤ 20 mmHg), hypothermia (T < 32 °C), metabolic 
acidosis (pH < 7.3), and coagulopathy (ROTEM clot ampli-
tude <35 mm at 5 min). There was no significant difference 
in acidemia (pH, pCO2, BE, lactate), temperature, hemody-
namic status (HR and MAP) or ROTEM between the two 
groups after the 90 min of traumatic hemorrhage. The hem-
atocrit did not differ between the two groups after hemor-
rhage and resuscitation (Fig. 3).
Resuscitation phase
Hemodynamic status
Immediately after initiation of ECMO, the HR and MAP 
improved and after 60 min the animals were close to a 
normal circulatory state. After resuscitation in the con-
trol group the HR and MAP increased during the first 30 
min. MAP never exceeded 40 mmHg and then decreased 
again. There was a significant difference in MAP, favoring 
the ECMO group, after 60 min of resuscitation (Fig. 4). 
Although no specific immune testing of the blood was per-
formed, no signs of adverse effects of the allogeneic blood 
transfusions were observed.
Fig. 3  The Hematocrit during the study. The exsanguination and 
transfusion in the two groups were equal. Control (solid line) ECMO 
(dashed line)
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Ventilation and ECMO
The animals were equally saturated in both groups during 
baseline and hemorrhage. After resuscitation and before 
circulatory arrest pO2 in the control group was above nor-
mal (mean 27.0 kPa) due to increased oxygen in the venti-
lator. No arterial blood gas was performed in ECMO group 
due to a lack of central arterial access and no AV-bridge 
in the circuit. Instead pre-oxygenator blood gas was drawn 
reflecting the rabbit’s respiratory status and acid–base sta-
tus. The pCO2 (Table 1) was equal in the two groups, both 
at the end of the hemorrhage phase and after resuscitation. 
A limited stable ECMO flow of 100 ml/min was obtained.
Acid–base balance
There was a significant fall in pH, decrease in BE, and rise in 
lactate, in both groups during the traumatic hemorrhage phase 
(Fig. 5a, b; Table 1). The lactate concentration slowly started 
to fall with ECMO but continued to rise in the control group 
after resuscitation. At the end of the resuscitation phase lac-
tate was significantly lower in the ECMO group. After 15 min 
of ECMO, pH started to increase and was over 7.0 after 
60 min. Meanwhile the pH continued to deteriorate in the 
control group. The difference in pH between the two groups 
after 60 min reached statistical significance. Base Excess 
started to increase after 30 min of ECMO treatment and was 
overall significantly improved compared to the control group.
Body temperature
ECMO significantly improved the animal’s body tempera-
ture and after 60 min of active warming the temperatures 
were almost normalized (>37 °C). The body temperatures 
remained low (below 30 °C) in the control group (Fig. 5c).
Coagulation in vitro (Table 1)
The contact pathway of coagulation was evaluated with 
aPTT and ROTEM Clotting Time, CTIntem. The aPTT 
decreased in the ECMO group during the 60 min of resus-
citation, while aPTT, in the control group, continued to rise. 
The difference between the two groups did not reach sta-
tistical significance. CTIntem increased in both groups, but 
even though there was no significant difference at the end 
of resuscitation, the rise was higher in the control group.
The tissue factor dependent extrinsic pathway of 
coagulation was analyzed by INR, ROTEM CTExtem, and 
CFTExtem. INR decreased after 60 min of ECMO while it 
remained on the same level in the control group.
The extem clotting time (CTExtem) was considerably 
reduced in the ECMO group, while it was largely prolonged 
in the control group and there was a difference between the 
groups at the end of the experiment. The clot formation 
time (CFTExtem) followed the same pattern and was signifi-
cantly reduced in the ECMO group after resuscitation.
Analyzing the clot firmness with ROTEM: MCFExtem 
(reflecting both platelet and fibrinogen contribution) was 
slightly increased after ECMO for 60 min. while it was 
reduced in the control (p = 0.2). The MCFFibtem (only 
fibrinogen contribution) showed low detectable values 
at the end of the experiments equally in both groups. The 
Fibrinogen levels were also equally diminished in the two 
groups and did not increase after transfusion.
Neither in the study group nor in the control group, did 
the ROTEM curves show any fibrinolysis. Analyses with 
HEPTEM, blocking the heparin effect, did not change the 
INTEM CT or CFT variables. This indicates that the sys-
temic effect of surface heparin was negligible.
The platelet count was equal in the two groups initially but 
after 90 min of hemorrhagic shock the platelet count was lower 
in the ECMO group. The number of circulating platelets kept 
falling and was at the end of the resuscitation phase significantly 
reduced in the ECMO group compared to the control group.
Coagulation in vivo (Table 1)
The baseline bleeding times according to EBT and CBT 
were equal in the two groups. After resuscitation both the 
difference in EBT and CBT were statistically significant, 
favoring the ECMO group.
Outcome and survival
In the ECMO group, three animals (3/5) were asystolic and 
one was severely bradycardic (HR < 10) at cannulation. 
Fig. 4  The animals’ mean arterial pressure during the study. At 
90 min after hemorrhagic shock there was no difference in mean arte-
rial pressure between the two groups but after 60 min of resuscita-
tion the mean arterial pressure in the ECMO group was significantly 
improved (p = 0.01 respectively). Control (solid line) ECMO (dashed 
line)
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They all received external cardiac compressions and recov-
ered with recapture of sinus rhythm and normalized blood 
pressure after initiation of extracorporeal circulation. In 
summary, all animals (5/5) in the ECMO group survived 
with stabilized vital status and improved coagulation. Two 
animals (2/5) in the control group were asystolic, 28 min, 
respectively, 30 min after initiation of resuscitation (trans-
fusions were completed in both cases). They received exter-
nal cardiac compressions but did not regain sinus rhythm. 
The surviving animals in the control group (3/5) were all 
severely hypotensive and hypothermic.
Discussion
Trauma-induced coagulopathy is an important factor for 
hemorrhagic death in trauma victims [7]. When fully devel-
oped, the coagulopathy is very difficult to reverse. This 
study shows that VA-ECMO improves acidosis and tem-
perature in a traumatic experimental hemorrhagic model. 
The heater in the ECMO circuit was superior compared 
to warm transfusions and heating mattress in the con-
trol group. ECMO increased the temperature above 37 °C 
and increased pH above 7.0 within 60 min. ECMO also 
improved central circulation in terms of blood pressure and 
heart rate. When assisted by VA-ECMO all the animals in 
severe hemorrhagic shock survived. The extrinsic coagula-
tion pathway reflected by clot formation time (CFTExtem) 
was improved and there was a trend of improvement in the 
intrinsic pathway as well. In vivo testing of the coagula-
tion capacity with ear bleeding and cuticle bleeding times 
showed an improvement in the ECMO group.
To our knowledge no similar study has previously been 
performed. This rabbit ECMO model was earlier used eval-
uating the Factor XII antibody 3F7 [20]. ECMO has previ-
ously been used in a rabbit-trauma model where ECMO-
resuscitation for prolonged hemorrhagic shock (3 h) 
improved tissue perfusion, reduced systemic inflamma-
tion, and alleviated the intestinal damage that may be one 
important factor for Multi Organ Failure (MOF) [24]. Park 
et al. showed that rats exposed to both hemorrhagic shock 
and hypothermia have a prolonged clot formation time and 
reduced MCF [25]. The former finding is verified by the 
present results, but ECMO only slightly improved the clots 
firmness. This may be due to the consumption of fibrino-
gen. The fibrinogen levels were equally reduced after hem-
orrhagic shock in both groups and the ECMO system did 
not seem to aggravate fibrinogen consumption.
Apart from a lower platelet count and much higher 
CTExtem and CFTExtem in the ECMO group after hemor-
rhagic shock there was no difference between the groups 
before resuscitation.
Table 1  Blood and coagulation
Baseline represents all animals. The control and ECMO groups are compared after hemorrhagic shock (90 min) and after resuscitation (150 min) 
and p values are calculated with Rank-Sum Test. P1 90 min, P2 150 min Values presented as Means with SEM
Temp temperature, BE base excess, Hb hemoglobin, PLT platelets, aPTT activated partial thromboplastin time, INR international normalized 
ratio (a Ratio of Prothrombine Time), CTExt clotting time extrinsic, CFTExt clot formation time extrinsic, MCFExt maximum clot firmness extrin-
sic, CTInt clotting time intrinsic, MCFFib maximum clot firmness fibtem, EBT ear bleeding time, CBT cuticle bleeding time
Baseline, 0 min Control, 90 min ECMO, 90 min P1 Control, 150 min ECMO, 150 min P2
Temp (°C) 38.4 ± 0.1 30.3 ± 0.4 30.7 ± 0.2 0.34 29.3 ± 0.4 37.3 ± 0.3 0.01
pH 7.44 ± 0.01 7.20 ± 0.04 7.16 ± 0.10 0.38 6.90 ± 0.03 7.08 ± 0.04 0.01
pCO2 (kPa) 7.11 ± 0.25 5.90 ± 0.89 6.13 ± 0.64 0.75 7.02 ± 0.93 7.48 ± 0.54 0.46
Lactate (mM) 1.07 ± 0.05 11.6 ± 1.4 8.9 ± 1.1 0.10 14.3 ± 1.1 7.8 ± 0.7 0.01
BE (mM) 2.79 ± 0.03 −12.3 ± 1.8 −14.3 ± 2.3 0.26 −21.4 ± 0.5 −16.2 ± 1.0 0.01
Hb (g/L) 134 ± 3 56 ± 4 62 ± 3 0.17 90 ± 16 93 ± 8 0.45
PLT × 109/l 193 ± 17 131 ± 23 93 ± 18 0.17 149 ± 20 85 ± 17 0.02
aPTT (s) 14.4 ± 2.6 20.6 ± 4.3 17.7 ± 2.7 0.16 29.0 ± 87 11.0 ± 23 0.07
INR 0.9 ± 0.0 1.3 ± 0.15 1.74 ± 0.33 0.20 1.36 ± 0.09 1.44 ± 0.2 0.42
Fibrinogen (g/l) 2.2 ± 0.0 1.2 ± 0.3 0.9 ± 0.2 0.38 1.3 ± 0.2 1.0 ± 0.2 0.38
CTExt (s) 45 ± 2 69 ± 4 764 ± 687 0.04 827 ± 710 79 ± 8 0.17
CFTExt (s) 42 ± 1 170 ± 14 1141 ± 965 0.46 1770 ± 1001 111 ± 19 0.01
MCFExt (mm) 66.7 ± 0.5 51.2 ± 0.9 42.2 ± 10.4 0.30 35.6 ± 10.6 51.6 ± 2.8 0.20
CTInt (s) 181 ± 28 262 ± 357 245 ± 64 0.46 948 ± 693 290 ± 93 0.34
MCFFib (mm) 11.3 ± 0.5 4.0 ± 0.3 4.2 ± 1.0 0.33 3.4 ± 1.0 4.8 ± 1.0 0.19
EBT (s) 66.0 ± 9.0 – – – 162.0 ± 21.0 55.5 ± 7.0 0.01
CBT (s) 70.5 ± 10.5 – – – 174.0 ± 15.0 75.0 ± 13.0 0.01
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In spite of the initial advanced coagulopathy, several 
coagulation parameters improved after ECMO-resuscita-
tion. Engstrom et al. showed the importance of an increased 
pH and reduced lactic acidosis to avoid impairment of 
the coagulation cascade in two previous studies [12, 26]. 
We believe that the improvement of tissue perfusion with 
ECMO resulted in a gradual normalization of pH and lac-
tate. This may have had a beneficial effect on the coagula-
tion capacity. To gain efficiently strong clots after this type 
of trauma it is necessary to substitute fibrinogen. In the pre-
sent study the fibrinogen was consumed, stayed on a low 
level and was not substituted. This was verified by a reduc-
tion of the maximum clot firmness. These findings suggest 
that the reduction was mainly due to low fibrinogen levels. 
In a clinical setting fibrinogen would have been substituted.
Extracorporeal devices activate the coagulation system 
[27] and previous studies have shown decreased num-
bers of circulating platelets in extracorporeal devices [28, 
29]. This finding was confirmed in the present study. The 
number of circulating platelets did not reach levels below 
50x109/L and the clotting ability did not seem to be neg-
atively affected. ECMO in trauma has been somewhat 
controversial but has in recent years gained popularity 
both in the post-trauma ARDS situation and in hypov-
olemic shock during the early resuscitation phase [16]. In 
our clinical experience, we have successfully resuscitated 
selected patients with respiratory failure and concomitant 
hemorrhagic shock due to thoraco-abdominal trauma with 
venoarterial ECMO (unpublished data). In this model no 
intentional pulmonary injury was induced. A high pO2 in 
the control group supports this. ECMO improves both 
hypoxic metabolic acidosis and hypercapnic respiratory 
acidosis. In combination with lung injury ECMO may 
add further positive effects on the traumatic coagulopathy. 
An earlier experimental study described how VA-ECMO 
reduced systemic venous pressure while maintaining or 
improving systemic perfusion in both a normal circulatory 
state and in the setting of increased right ventricular load 
associated with acute lung injury [30]. ECMO may theoret-
ically be a useful tool in reducing blood loss during major 
venous hemorrhage, but other positive or negative effects 
of ECMO in trauma need to be investigated.
There have been concerns about using heparin in trauma 
patients on ECMO. We did not use systemic heparin as 
anticoagulant for the ECMO system but heparinized sur-
faces of tubings and oxygenators. The blood used for prim-
ing the circuit was citrated with the same concentration as 
blood products that are normally transfused to trauma vic-
tims. Calcium was substituted as needed. Viscoelastic hep-
arin test did not show any effect of free heparin in the sys-
tem. The aPTT were reduced during ECMO treatment but 
there were no signs of clotting in the circuits. In the future 
it may be possible to use anticoagulant drugs that do not 
affect the bleeding risk [20].
Inflammation and coagulation are largely activated in 
ECMO systems [31]. In this study we did not focus on the 
immune system or inflammation. The aim was to study the 
effect of ECMO support on hypothermia, acidosis, and 
Fig. 5  a, b The animals acid–base balance during the study. 90 min 
after hemorrhagic shock there was no difference in Base Excess (a) 
or pH (b) between the two groups. After 60 min of resuscitation 
the Base Excess and the pH were significantly higher in the ECMO 
group (p = 0.01, respectively). Control (solid line) ECMO (dashed 
line). c The animals’ body temperature. Initiation of ECMO increased 
the animals body temperature efficiently and after 60 min the animals 
in the ECMO group were significantly warmer (>37 °C) than the con-
trols (p = 0.001)
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coagulopathy in the first initial 60 min of trauma resuscita-
tion. The ability of ECMO to fast increase the body temper-
ature during this time is obvious but the reduction of lactate 
and improvement of pH is somewhat slower. If ECMO had 
been extended for more than 60 min or even continued for 
the first 24 post-trauma hours, the acid–base balance might 
have been improved further. ECMO in trauma may be per-
formed without heparin for at least 24 h.
A low ECMO flow was accepted due to limited drain-
age. This limitation was caused by hypovolemia and in this 
study a lack of further transfusion possibilities. In clinical 
trauma scenarios, continuous bleeding is a common prob-
lem which can cause difficulties to withhold a high ECMO 
flow. However, with the availability of donor blood, the 
ECMO circuit can quickly be filled with more blood, and 
the large bore cannulas are optimal for high volume infu-
sion [16].
There are some obvious limitations with our study. The 
number of study animals is small, especially as in the con-
trol group at the end of the study only three animals are 
left. The posttraumatic observation time was short, only 
150 min. The small animal model with rabbits was used 
because of earlier experience, but a large animal model 
may have been closer to a human scenario. The coagulation 
system in rabbits is slightly different compared to humans 
but their coagulation system is constructed as the human 
with extrinsic, intrinsic and a common pathway’s and con-
sists of the same coagulation factors. Some serin protease 
activities are different. Rabbits have a 50 times higher 
activity of factor V than humans and the activity of factor 
XI and factor XIII is also slightly higher. This may explain 
why rabbits have shorter aPTT and PT [32]. The different 
activity may limit implications for human management and 
the variations of our coagulation data may be explained by 
a limited time of ECMO-resuscitation. Furthermore, it is 
difficult to simulate a realistic traumatic model with coagu-
lopathy in animals [33]. However, this is the first experi-
mental pilot study showing ECMO’s effect on temperature, 
acidosis, and coagulation in a rabbit model of trauma and 
hemorrhage. Further studies to evaluate ECMO’s role in 
trauma are needed and indications for VA-ECMO in severe 
trauma need to be established in collaboration between the 
trauma communities and ECMO communities.
Conclusions
VA-ECMO seems beneficial in an experimental traumatic 
hemorrhagic shock model for stabilization of central hemo-
dynamics, improvement of acidosis, body temperature, and 
coagulopathy during the initial resuscitation phase. ECMO 
may increase the likelihood of survival but this need to be 
confirmed in larger future studies.
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